ShockWave Medical Inc CFO Dan Puckett Sells 3,229 Shares
On February 5, 2024, Dan Puckett, the CFO of ShockWave Medical Inc (NASDAQ:SWAV), sold 3,229 shares of the company's stock. The transaction was filed with the SEC and can be found in detail through the following SEC Filing.
ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company offers innovative solutions that are designed to address the needs of patients with calcified plaque in their arteries.
Over the past year, the insider has sold a total of 15,740 shares and has not made any purchases of the company's stock.
The insider transaction history for ShockWave Medical Inc shows a pattern of selling activity, with 0 insider buys and 46 insider sells over the past year.
On the day of the insider's recent sale, shares of ShockWave Medical Inc were trading at $231.15, resulting in a market cap of $8.730 billion.
The price-earnings ratio of the stock stands at 36.86, which is above the industry median of 26.98 but below the company's historical median price-earnings ratio.
With the current share price of $231.15 and a GuruFocus Value of $534.88, ShockWave Medical Inc has a price-to-GF-Value ratio of 0.43. This indicates that the stock is considered a Possible Value Trap, Think Twice according to its GF Value.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
